Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

Alexandra Levine, M.D.

Committee:	Oncologic Drugs Advisory Committee	
Meeting Date:	September 7, 2006	
I acknowledge that contingent upon public disclosure of the financial interest listed below, related to new drug application (NDA) 21-660, Abraxane (paclitaxel protein-bound particles for injectable suspension)(albumin-bound), sponsored by Abraxis BioScience, Inc., including trial design issues for adjuvant treatment of node-positive breast cancer, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).		
Type of Interest	Nature	Magnitude
Unrelated Speaker's Bure	eau Competitor	Less than \$10,001 per year
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest, the waiver is not valid.		
<u>/s/</u>		/4/06
Signature		Pate